CRISPR Therapeutics

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Cathie Wood's ARKK

Analyst Color

Equities

Large Cap

Sector ETFs

Econ #s

Analyst Ratings

Tech

ETFs

ARKK

COIN

CRSP

HOOD

PLTR

RBLX

ROKU

SHOP

TSLA

ARKK supera al Nasdaq con entradas récord y un rally basado en beneficios reales e innovación tecnológica.

ARKK supera al Nasdaq impulsado por beneficios reales: el ETF de Cathie Wood vuelve a brillar

Time magazine

Long Ideas

Media

Trading Ideas

AMZN

ASML

BABA

BYDDF

BYDDY

CMCSA

COUR

DASH

DUOL

ENGIY

EQNR

ESLOY

GILD

GOOG

GOOGL

HYMTF

LRLCY

MELI

MSFT

NFLX

NTDOY

ONON

PMRTY

SFTBF

SFTBY

UMGNF

UNVGY

TIME revela las 100 empresas más influyentes de 2025. Conoce las compañías en bolsa que lideran innovación y crecimiento este año.

Las empresas más influyentes de 2025 según TIME: ¿Cuáles están en bolsa?

Crispr Therapeutics

Health Care

Markets

ARKG

VRTX

Cathie Wood señala dos acciones biotecnológicas con potencial de crecimiento explosivo gracias a la revolución genética y la IA.

Cathie Wood apuesta por la biotecnología: estas dos acciones podrían multiplicarse por diez

CRISPR Therapeutics AG

Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth

Small Cap

Opinion

Press Releases

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Earnings

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

News

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

General

CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Australia's Largest University Establishes 'Monash Boston Hub' to Accelerate Global Biotech Partnerships and Licensing

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

ADIA

AVAI

BNTX

CLDI

CTMX

FATE

IBRX

MESO

Abivax

Arcellx

Akero Therapeutics

Alkermes

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Caris Life Sciences

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Krystal Biotech

Kymera Therapeutics

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Merus

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Nuvalent

Vaxcyte

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

uniQure

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

TG Therapeutics

Viking Therapeutics

B of A Securities

Needham

HC Wainwright & Co.

JP Morgan

Comments

CRISPR Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL